|
AU2016253674A1
|
|
Pharmaceutical composition
|
|
AU2016225887A1
|
|
Pharmaceutical composition
|
|
AU2016201136A1
|
|
Pharmaceutical compositions
|
|
AU2015264939A1
|
|
Formulations and methods for attenuating respiratory depression induced by opioid overdose
|
|
AU2015200402A1
|
|
Pharmaceutical composition
|
|
AU2015200313A1
|
|
Pharmaceutical composition
|
|
AU2014250614A1
|
|
A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
|
|
AU2014216032A1
|
|
Pharmaceutical composition
|
|
AU2014216026A1
|
|
Pharmaceutical composition
|
|
US2014056975A1
|
|
Pharmaceutical Composition
|
|
AU2013211445A1
|
|
Pharmaceutical Compositions
|
|
AU2012213056A1
|
|
Pharmaceutical composition comprising opioid agonist and sequestered antagonist
|
|
CA2814230A1
|
|
Formulations and methods for attenuating respiratory depression induced by opioid overdose
|
|
US2009196890A1
|
|
Pharmaceutical compositions
|
|
AU2008346870A1
|
|
Pharmaceutical composition
|
|
AU2008338439A1
|
|
Pharmaceutical composition
|
|
CA2709950A1
|
|
Pharmaceutical composition
|
|
US2010151014A1
|
|
Pharmaceutical composition
|
|
EP2484346A1
|
|
Pharmaceutical compositions
|
|
AU2006247349A1
|
|
Morphine sulphate formulations
|
